<DOC>
	<DOC>NCT00002436</DOC>
	<brief_summary>To evaluate the safety and efficacy of low and high doses of lamivudine ( 3TC ) in combination with zidovudine ( AZT ) and zalcitabine ( dideoxycytidine; ddC ) in combination with AZT. PER 02/27/95 AMENDMENT: To evaluate the efficacy and safety of both blinded and open-label combination therapy.</brief_summary>
	<brief_title>The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT</brief_title>
	<detailed_description>Patients are randomized to one of three treatment arms: low-dose 3TC plus AZT, high-dose 3TC plus AZT, or ddC plus AZT. Treatment continues for 32 weeks, with possible extension to 52 weeks. PER 02/27/95 AMENDMENT: Patients may continue therapy on AZT and low-dose 3TC on an open-label basis. Open-label therapy continues with follow-up every 8 weeks until intolerable toxicity occurs or study terminates.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Patients must have: HIV positivity. CD4 count 100300 cells/mm3. Prior AZT therapy for 24 or more weeks and currently on AZT. Exclusion Criteria Patients with the following prior conditions are excluded: History of intolerance to AZT. History of grade 2 or worse peripheral neuropathy. Prior Medication: Excluded: Any prior antiretroviral therapy other than AZT. Required: Concomitant AZT therapy. Required: At least 24 weeks of prior AZT.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1994</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Drug Therapy, Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
</DOC>